Navigation Links
NSAIDs Won't Shield Against Skin Cancer
Date:2/15/2010

Researchers find anti-inflammatories show no effect on squamous cell carcinoma

MONDAY, Feb. 15 (HealthDay News) -- Countering prior indications that long-term use of NSAID painkillers might help reduce cancer risk, a new study suggests that these anti-inflammatory drugs offer no protection against a common skin cancer.

Previous research had suggested that routine use of NSAIDs -- including such over-the counter medications as Advil, Motrin, aspirin, Celebrex and Aleve (but not Tylenol) -- is associated with a reduced risk for the onset of colorectal, breast, prostate and lung cancer.

"Although there is some prior evidence, mostly laboratory-based, to suggest that NSAIDs can reduce the risk for the particular type of skin cancer called cutaneous squamous cell carcinoma, in our study, we didn't find that association," said the lead author, Dr. Maryam M. Asgari, an investigator in the research division at Kaiser Permanente Northern California (KPNC) in Oakland, Calif.

The study, which was supported by the U.S. National Institute of Arthritis and Musculoskeletal and Skin Diseases and the U.S. National Cancer Institute, are published in the Feb. 15 online issue of the Archives of Dermatology.

To explore the potential connection between NSAIDs and skin cancer risk, Asgari and her colleagues administered questionnaires to a randomly selected pool of 415 patients between the ages of 43 and 85 who were diagnosed with skin cancer in 2004 and sought care at KPNC.

This group's self-reported NSAID-use history between 1994 and 2004 was stacked up against that of a group of 415 healthy patients. Both groups were similar in terms of age, race and gender. As well, records detailing pharmacy-dispensed NSAID patterns among all the patients were also examined for links to skin cancer incidence.

The authors noted that 61 percent of all the patients reported routine use of NSAIDs in the decade preceding the study. Specifically, 48 percent said they had used aspirin, 18 percent ibuprofen, 5 percent naproxen (ie, Aleve), and 4 percent nabumetone (Relafen).

But regardless of dosage used, type of medication taken, and/or whether NSAIDs were pharmacy-dispensed, the anti-inflammatory drugs were not found to be associated with a drop in skin cancer risk.

In fact, those patients who had taken NSAIDs for a relatively short period of time --anywhere from one to three years-- actually appeared to have a slightly increased risk for developing squamous cell carcinoma, the researchers said.

They concluded that NSAIDs did not seem to offer any protective effect with respect to skin cancer, and -- given the potential toxic side-effects of long-term NSAID use -- they suggested that patients at higher risk for skin cancer should be directed towards other safer, and perhaps more effective, interventions.

"We were surprised at the lack of NSAID protection," Asgari remarked. "Particularly when we saw an increased risk for skin cancer associated with the short-term use of NSAIDs. But actually that's not been unheard of, and I think there could be various explanations for this. Maybe people using NSAIDs short-term have other co-morbidities that make them more prone to having a weaker immune system and having poorer health. And also there are some forms of NSAIDs that do make you sun-sensitive, and more prone to getting DNA damage. That might be another explanation. But we were surprised."

However, Eric Jacobs, strategic director of pharmaco-epidemiology for the American Cancer Society, said Asgari's findings were not surprising.

"Results from this study are consistent with those of most previous studies," he said. "The best way to lower the risk of non-melanoma skin cancer, including squamous cell carcinoma, is to limit your exposure to strong sunlight -- for example by wearing a hat and using sunscreen -- and to avoid using tanning beds and sun lamps."

Dr. Alfred I. Neugut, head of cancer prevention and control at Columbia University's cancer center in New York City, also found the study's results unsurprising.

"Cutaneous squamous cell carcinoma is not your typical, run-of-the-mill cancer," noted Neugut, who is also co-director of cancer prevention at New York Presbyterian Hospital. "While it's one of the most common cancers -- maybe the most common -- it's not aggressive, not systemic, and related almost exclusively to sun exposure. So it is not really in the same category of cancers as, say, colorectal cancer or breast cancer."

Neugut added, "The fact that they found [NSAID use] has no effect is logical."

More information

For additional information on skin cancer risk, visit the American Cancer Society.



SOURCES: Maryam M. Asgari, M.D., M.P.H., investigator, division of research, Kaiser Permanente Northern California, Oakland, California; Eric Jacobs, PhD, strategic director of pharmaco-epidemiology, American Cancer Society, Atlanta; Alfred I. Neugut, M.D., PhD, head of cancer prevention and control, Herbert Irving Comprehensive Cancer Center, Columbia University, and co-director, cancer prevention, New York Presbyterian Hospital, New York City; Feb. 15, 2010, online Archives of Dermatology


'/>"/>
Copyright©2010 ScoutNews,LLC.
All rights reserved

Related medicine news :

1. Early Use of NSAIDs Might Prevent Alzheimers
2. NSAIDs Might Lower Breast Cancer Risk
3. NSAIDs: Painkillers, inflammation inhibitors, anti-cancer drugs and new de-methylating agents
4. NSAIDs No Better for Low Back Pain
5. NSAIDs Protect Against Parkinsons Disease
6. Link Uncovered Between Benign Prostatic Hyperplasia and NSAIDs, Says Harvard Mens Health Watch
7. Using coxibs and NSAIDs to treat osteoarthritis
8. Strict Blood Sugar Lowering Wont Ease Diabetes Heart Risk
9. Blue Cross and Blue Shield Association Expands Blue Distinction(R) Designation to Include Spine Surgery, Knee and Hip Replacement
10. Blue Cross and Blue Shield of Illinois Offers BlueCare Dental Plan
11. Blue Cross Blue Shield of Massachusetts Urges Members to Get Their Flu Shot
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/28/2017)... ... 28, 2017 , ... Calibration, qualification, and the appropriate level ... maintaining GMP and USP compliance. In a new webinar from METTLER TOLEDO entitled ... these requirements are explained. The challenge is to determine how to put ...
(Date:3/28/2017)... ... March 28, 2017 , ... Neurotechnology ... two biometric time and attendance tracking products: the new NCheck Cloud Bio Attendance ... Bio Attendance uses biometric face recognition to enable users to check in and ...
(Date:3/28/2017)... ... March 28, 2017 , ... ... the Self-Funding Success website has recently developed and published an informational resource that ... was created based on common inquiries the site’s team of third party administrator ...
(Date:3/28/2017)... ... March 28, 2017 , ... A minimally invasive ... “perfect smile.” The National Association of Dental Laboratories (NADL) is informing dentists about ... aware of when utilizing dental laboratories and technicians that create these veneers. ...
(Date:3/28/2017)... ... 2017 , ... Public relations pros work hard to earn placements and ... While many results are clear, much of PR is hard to quantify. Goal-setting and ... to measurement, firms should always take an all-inclusive approach that takes both traditional and ...
Breaking Medicine News(10 mins):
(Date:3/28/2017)... , March 28, 2017 The ... reach USD 8.0 billion by 2025, according to a ... incidence of infectious diseases and cancer is expected to ... disease diagnosis over the coming years. In addition, higher ... autologous and allogenic stem cell therapy, due to adverse ...
(Date:3/27/2017)... 27, 2017 Summary This ... Eli Lilly and its partnering interests and activities since 2010. ... provides an in-depth insight into the partnering activity of one ... demand company reports are prepared upon purchase to ensure inclusion ... The report will be delivered in PDF format ...
(Date:3/27/2017)... Columbia , March 27, 2017 LightIntegra ... has appointed William "Bill" Dubiel as President and Chief ... also elected to the Board of Directors of LightIntegra. ... the Executive Chairman of LightIntegra. "This ... next President and Chief Executive Officer. We,ve selected a ...
Breaking Medicine Technology: